Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNA CART19 in Relapsed/Refractory Hodgkin Lymphoma
NCT02277522Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Oct 2014
- Primary completion
- Nov 2016
- Modality
- CAR-T Cells, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RNA CART19 cells in Hodgkin lymphoma (HL), sponsored by University of Pennsylvania. Primary endpoint: Number of Adverse Events at 2 years. Started Oct 2014; status: terminated.
02
Drugs
RNA CART19 cells
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02277522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02277522.